Related Experiment Video
Updated: Jul 21, 2025
Measurement of Antibody Effects on Cellular Function of Isolated Cardiomyocytes
Published on: March 8, 2013
Differential Detection of O-GlcNAcylated proteins in the heart using antibodies
Bhargavi Narayanan1, Fiddia Zahra1, Russell A Reeves2
1The Department of Biological Chemistry at the Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.
Abstract:
Thousands of mammalian intracellular proteins are dynamically modified by O-linked β-N-acetylglucosamine (O-GlcNAc). Global changes in O-GlcNAcylation have been associated with the development of cardiomyopathy, heart failure, hypertension, and neurodegenerative disease. Levels of O-GlcNAc in cells and tissues can be detected using numerous approaches; however, immunoblotting using GlcNAc-specific antibodies and lectins is commonplace. The goal of this study was to optimize the detection of O-GlcNAc in heart lysates by immunoblotting. Using a combination of tissue fractionation, immunoblotting, and galactosyltransferase labeling, as well as hearts from wild-type and O-GlcNAc transferase transgenic mice, we demonstrate that contractile proteins in the heart are differentially detected by two commercially available antibodies (CTD110.6 and RL2). As CTD110.6 displays poor reactivity toward contractile proteins, and as these proteins represent a major fraction of the heart proteome, a better assessment of cardiac O-GlcNAcylation is obtained in total tissue lysates with RL2. The data presented highlight tissue lysis approaches that should aid the assessment of the cardiac O-GlcNAcylation by immunoblotting.
Insights
Detecting O-linked β-N-acetylglucosamine (O-GlcNAc) in heart tissue is crucial for understanding diseases. This study optimizes immunoblotting methods, finding the RL2 antibody superior for assessing cardiac O-GlcNAcylation in total lysates.
Area of Science:
- Biochemistry
- Molecular Biology
- Cardiovascular Research
Background:
- O-linked β-N-acetylglucosamine (O-GlcNAc) is a dynamic post-translational modification found on thousands of intracellular proteins in mammals.
- Aberrant O-GlcNAcylation is linked to various pathologies, including cardiomyopathy, heart failure, hypertension, and neurodegenerative diseases.
- Accurate detection of O-GlcNAc levels in tissues is essential for studying these conditions.
Purpose of the Study:
- To optimize the detection of O-linked β-N-acetylglucosamine (O-GlcNAc) in cardiac tissue lysates using immunoblotting.
- To compare the efficacy of different antibodies and tissue lysis approaches for assessing cardiac O-GlcNAcylation.
- To improve the reliability of O-GlcNAc detection in heart samples for disease research.
Main Methods:
- Utilized tissue fractionation and immunoblotting techniques.
- Employed galactosyltransferase labeling for enhanced detection.
- Compared two commercially available O-GlcNAc antibodies (CTD110.6 and RL2) using hearts from wild-type and O-GlcNAc transferase transgenic mice.
Main Results:
- Demonstrated differential reactivity of antibodies CTD110.6 and RL2 towards cardiac contractile proteins.
- Showed that CTD110.6 has poor reactivity with contractile proteins, which constitute a major portion of the heart proteome.
- Concluded that the RL2 antibody provides a better assessment of cardiac O-GlcNAcylation when used with total tissue lysates.
Conclusions:
- The choice of antibody and tissue lysis method significantly impacts the assessment of cardiac O-GlcNAcylation.
- The RL2 antibody is recommended for detecting O-GlcNAc in total heart lysates due to its superior reactivity with contractile proteins.
- Optimized immunoblotting approaches using RL2 can enhance the study of cardiac O-GlcNAcylation and its role in cardiovascular diseases.
